Emerald
UK-based healthtech company reimagining preventive care. Combining diagnostics, AI, and GP insights helps people take control of their health before symptoms appear. The platform’s AI engine analyses data from blood tests, wearables, and lifestyle inputs, identifying early warning signs and suggesting actionable steps —an integrated approach rarely found in existing NHS and private pathways.
Emerald has raised €3.4M across 3 funding rounds from 16 investors, most recently a round in Oct 2026. Based in London, UK; active in Healthtech. Data as of 28 Oct 2026.
London, UK
Total raised
€3.4M
€3,411,506
Funding rounds
3
Investors
16
distinct backers
Active since
2025-05
latest 2026-10
Funding by year
EUR raised per year · 2026 YTDEmerald — funding by year — interactive chart.
Data table
| Emerald — funding by year | |
|---|---|
| 2025 | €743k |
| 2026 | €2.7M |
Signals
High confidenceRaise-next likelihood11
base rate 30% for Other
- ▼ Raised very recently
- ▲ Up-round momentum
- ▼ Low backer re-investment
Exit likelihood13
base rate 11% (2+ rounds)
- ▼ Young (<3y)
- ▲ Recently backed by strong-exit-track investors
Timing: too soon vs cohort gap · momentum up. Funding-only estimates, not predictions and not investment advice — see signals.
Funding rounds
3 rounds| Date | Stage | Amount | Investors | |
|---|---|---|---|---|
| 2026-10-20 | Other | €1.7M | Existing investors,Highgoal Capital Management,Sequel | View deal → |
| 2026-01-29 | Pre-Seed | €1.0M | Angel Investors,BOOST&Co,Granatus Ventures,Innovate UK,Mark Fountain | View deal → |
| 2025-05-14 | Other | €743k | Harry Glorikian,Jane Austin,Johann Huber,Mart Abramov,Mike Benchimol,Nikolay Tretiakov+2 more | View deal → |